Major publication validates CTVQ for lung surgery
Filed with ASX · · 4 pages · English
Summary by 6ix AI
4DMedical Ltd. announces the validation of its CT:VQ™ technology for lung surgery through a major publication in a leading medical journal, highlighting its clinical value in patient selection for lung volume reduction surgery. The study indicates that using CT:VQ™ can significantly improve patient response rates to the surgery compared to traditional methods. This research was presented at the ATS International Conference, emphasizing the importance of integrating functional imaging into clinical workflows. The findings suggest that enhanced patient selection can lead to better economic outcomes for hospitals performing this specialized surgery.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Story so far
Earlier from 4DMedical
- GSK contract, UK clearance for CTVQ, and ASX 200 inclusion
- Insignia Financial to be removed from the S&P/ASX 200 Index
- 4DMedical receives CE Mark for CT: VQ™, enabling commercial launch across the European Union
- CE Mark for CTVQ and $83M placement to fund EU expansion
- CTVQ deployed at Mayo Clinic
Later from 4DMedical
- CTVQ enters US Outpatient Market via SimonMed 170 sites
- 4DMedical creates EU platform via contextflow acquisition
- 4DMedical targets US$2.5B PE market entry for CTVQ
- 4DMedical receives TGA approval for CTVQ in Australia
- 4DMedical Receives TGA Approval for CT: VQ™, Bringing Non-Contrast Ventilation-Perfusion Imaging to Australia
Follow 4DMedical into a list and get an email when it puts out news.
Follow 4DMedical